Skip to main content
SanofiIn development

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi has optioned and added a potential first-in-class oral small molecule immunology development candidate to its development pipeline from its research collaboration with Recursion.

Source

Article excerpt

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration. The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for more than $300 million in additional milestones under the program, with double digit royalties on net product sales, if approved. “The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines,” said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion. “Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline. With additional programs advancing across our collaboration, this milestone is another important demonstration of how our platform can translate computational capabilities into differentiated medicines - and do so repeatedly.” The potential first-in-class oral small...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted from this sentence

The candidate has now been added to Sanofi’s development pipeline and is expected to enter phase 1 clinical trials in 2027, with Sanofi funding and leading further development and commercialization to advance the program toward patients.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Takes effect
Oct 15, 2026
Location
Salt Lake City, Utah, United States

The full record

From the Signal API record

Details

Product
oral small molecule immunology development candidate

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
95%
Detected
Oct 15, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d96d86ca-bf78-9f9e-7450-c2433cbc395c returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "d96d86ca-bf78-9f9e-7450-c2433cbc395c",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-15T12:45:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/15/3381661/0/en/recursion-announces-sanofi-options-potential-first-in-class-immunology-development-candidate-from-their-collaboration.html",
    "title": "Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration",
    "excerpt": "Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration. The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for more than $300 million in additional milestones under the program, with double digit royalties on net product sales, if approved. “The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines,” said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion. “Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline. With additional programs advancing across our collaboration, this milestone is another important demonstration of how our platform can translate computational capabilities into differentiated medicines - and do so repeatedly.” The potential first-in-class oral small molecule...",
    "product": "oral small molecule immunology development candidate",
    "summary": "Sanofi has optioned and added a potential first-in-class oral small molecule immunology development candidate to its development pipeline from its research collaboration with Recursion.",
    "location": "Salt Lake City, Utah, United States",
    "planning": true,
    "image_url": "https://ml.globenewswire.com/Resource/Download/ef09be74-1f67-49ad-af66-b4366a7457c1",
    "confidence": 0.95,
    "product_data": {
      "name": "oral small molecule immunology development candidate",
      "full_text": "potential first-in-class oral small molecule immunology development candidate",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-10-15T12:45:00Z",
    "location_data": [
      {
        "city": "Salt Lake City",
        "state": "Utah",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-15",
    "article_sentence": "The candidate has now been added to Sanofi’s development pipeline and is expected to enter phase 1 clinical trials in 2027, with Sanofi funding and leading further development and commercialization to advance the program toward patients."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.